Your browser doesn't support javascript.
loading
Chemical Production of Cytotoxic Bispecific Antibodies Using the Ugi Multicomponent Reaction.
Vaur, Valentine; Koutsopetras, Ilias; Erb, Stéphane; Jackowska, Bianka; Benazza, Rania; Cahuzac, Héloïse; Detappe, Alexandre; Hernandez-Alba, Oscar; Cianférani, Sarah; Scott, Christopher J; Chaubet, Guilhem.
Afiliación
  • Vaur V; Bio-Functional Chemistry (UMR 7199), Institut du Médicament Strasbourg, University of Strasbourg, 74 Route du Rhin, 67400, Illkirch-Graffenstaden, France.
  • Koutsopetras I; Bio-Functional Chemistry (UMR 7199), Institut du Médicament Strasbourg, University of Strasbourg, 74 Route du Rhin, 67400, Illkirch-Graffenstaden, France.
  • Erb S; Laboratoire de Spectrométrie de Masse BioOrganique (LSMBO), Université de Strasbourg, CNRS, IPHC UMR 7178, 67000, Strasbourg, France.
  • Jackowska B; Infrastructure Nationale de Protéomique ProFI - FR2048, 67087, Strasbourg, France.
  • Benazza R; Patrick G Johnston Centre for Cancer Research, School of Medicine, Dentistry and Biomedical Sciences, Queen's University Belfast, Belfast, BT9 7BL, U.K.
  • Cahuzac H; Laboratoire de Spectrométrie de Masse BioOrganique (LSMBO), Université de Strasbourg, CNRS, IPHC UMR 7178, 67000, Strasbourg, France.
  • Detappe A; Infrastructure Nationale de Protéomique ProFI - FR2048, 67087, Strasbourg, France.
  • Hernandez-Alba O; Bio-Functional Chemistry (UMR 7199), Institut du Médicament Strasbourg, University of Strasbourg, 74 Route du Rhin, 67400, Illkirch-Graffenstaden, France.
  • Cianférani S; Institut de Cancérologie Strasbourg Europe, Strasbourg, France.
  • Scott CJ; Laboratoire de Spectrométrie de Masse BioOrganique (LSMBO), Université de Strasbourg, CNRS, IPHC UMR 7178, 67000, Strasbourg, France.
  • Chaubet G; Infrastructure Nationale de Protéomique ProFI - FR2048, 67087, Strasbourg, France.
Chembiochem ; : e202400170, 2024 May 07.
Article en En | MEDLINE | ID: mdl-38713134
ABSTRACT
Bispecific antibodies (bsAbs) have recently emerged as a promising platform for the treatment of several conditions, most importantly cancer. Based on the combination of two different antigen-binding motifs in a single macromolecule; bsAbs can either display the combined characteristics of their parent antibodies, or new therapeutic features, inaccessible by the sole combination of two distinct antibodies. While bsAbs are traditionally produced by molecular biology techniques, the chemical development of bsAbs holds great promises and strategies have just begun to surface. In this context, we took advantage of a chemical strategy based on the use of the Ugi reaction for the site-selective conjugation of whole antibodies and coupled the resulting conjugates in a bioorthogonal manner with Fab fragments, derived from various antibodies. We thus managed to produce five different bsAbs with 2 1 valency, with yields ranging from 20 % to 48 %, and showed that the affinity of the parent antibody was preserved in all bsAbs. We further demonstrated the interest of our strategy by producing two other bsAbs behaving as cytotoxic T cell engagers with IC50 values in the picomolar range in vitro.
Palabras clave

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Idioma: En Revista: Chembiochem Asunto de la revista: BIOQUIMICA Año: 2024 Tipo del documento: Article País de afiliación: Francia

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Idioma: En Revista: Chembiochem Asunto de la revista: BIOQUIMICA Año: 2024 Tipo del documento: Article País de afiliación: Francia